CYLIC POLYAMINES FOR BINDING PHOSPHATIDYLSERINE
The invention pertains to a compound for detecting cell death. According to the invention, the compound comprises a cyclic polyamine unit for the complexation of a bi- or trivalent metal ion. The compound of the invention may contain a reporting tag like fluorescein or a radioisotope including substituent.
1 . A compound characterized in that the compound comprises
at least one cyclic polyamine unit (C) for the complexation of bi- or trivalent metal ion or complexing bi- or trivalent metal ion
and pharmaceutical salt, diastereomere and enantiomere thereof.
2 . The compound according to claim 1 wherein the compound comprises further
at least one Tag (T) or linker (L)-Tag (T), and/or
at least one Bridge unit (B) or a bound,
3 . The compound according to claim 1 wherein the cyclic polyamine unit (C) is a
substituted or non-substituted moiety having from 9 to 20 ring members and from 3 to 6 amine nitrogens in the ring spaced by 2 or more carbon atoms from each other.
4 . The compound according to claim 3 wherein the cyclic polyamine unit (C) is selected from cyclen of formula Ia,
cyclam of formula Ib and
cyclen-cyclam mix of formula Ic
wherein R1, R2, R3 and R4 are independently from each other selected from bond, Hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy or Alkyl—COO—, Aryl—COO—.
5 . The compound according to claim 1 , wherein the bivalent metal ion is chosen from the group consisting of Zn 2+ , Ca 2+ , Cu 2+ , Be 2+ , Mg 2+ , Sr 2+ , Ba 2+ , Cd 2+ , Cr 2+ , Mn 2+ , Fe 2+ , Co 2+ , Ni 2+ , Pb 2+ and Hg 2+ .
6 . The compound according to claim 1 , wherein the trivalent metal ion is chosen from the group consisting of Al 3+ , Ga 3+ , In 3+ , Cr 3+ , Mn 3+ , Fe 3+ , Co 3+ and Ni 3+ .
7 . The compound according to claim 1 wherein the Tag (T) or the Tag of the linker (L)-Tag (T) group is a detectable label wherein the detectable label is covalently bound to one or more cyclic polyamine units (C) or Bridge unit (B).
8 . The compound according to claim 7 wherein the Tag (T) is chosen from the group comprising fluorescent dyes, enzymes, proteins, and radioactive labels.
9 . The compound according to claim 8 , wherein
the fluorescent dye is chosen from the group comprising of fluoresceins, rhodamines, BODIPY, Cy-3, Cy-5, and derivatives thereof.
the protein is chosen from the group comprising of peroxidases, luciferases, biotin, avidin, and antibodies or parts thereof;
the radioactive label is chosen from the group comprising of 99m Tc, 18 F, 11 C, 124 I, 123 I, 64 Cu 2+ , 68 Ga 3+ , 111 I 3+ , 14 C, 3 H, 32 P, and 33 P, preferably 18 F.
10 . The compound according to claim 1 wherein the Tag (T) or the linker (L)-Tag (T) is bound to the cyclic polyamine unit or to the Bridge unit (B).
11 . The compound according to claim 1 wherein linker (L) is selected from
C 1 -C 6 alkyl, O—C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylene, (CH 2 CH 2 O) n CH 2 CH 2 , substituted or non-substituted aryl, substituted or non-substituted O—aryl, substituted or non-substituted heteroaryl, (CH 2 ) n Ph, (CH 2 CH 2 CH 2 O) n CH 2 CH 2 , CO(CH 2 ) n ,[O(CH 2 ) n —O(CH 2 ) n ] m , or —O(CH 2 ) n , [O(CH 2 ) n —O(CH 2 ) n ] m wherein Ph=phenyl and n or m=1, 2, 3, 4, 5, 6.
12 . The compound according to claim 1 wherein
the Bridge unit (B) is connecting the cyclic polyamine unit (C) when there are at least two cyclic polyamine units (C) or
the Bridge unit (B) is bound to a single cyclic polyamine unit (C).
13 . The compound according to claim 12 wherein the Bridge unit (B) is selected from the group comprising the substituted or non-substituted moiety described below
wherein X1, X2 and X3 are independently from each other a H, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylene, C(O), [O(CH 2 ) n ] m , (CH 2 CH 2 O) m , CH 2 OPhCH 2 , (CH 2 CH 2 CH 2 O) m , (CONHPhCH 2 ), (CONH(CH 2 CH 2 O) 2 CH 2 CH 2 ), [O(CH 2 ) n ] m —NH 2 , or C(O)NH—[(CH 2 ) n —O] m , Ph=phenyl, n=2 to 6 and m=1 to 6,
Formula V′ is a linear peptide consisting of α-amino acids and
Formula V′a is a linear peptide consisting of α-amino acids.
14 . A pharmaceutical composition, comprising a compound of claim 1 and optionally a suitable carrier and/or additive.
15 . A method comprising using a compound according to claim 1 for binding phosphatidylserine.
16 . A method comprising using a compound according to claim 1 for cell death (apoptosis, necrosis) imaging.
17 . The compound according to claim 1 for the manufacture of a pharmaceutical composition for cell death (apoptosis, necrosis) imaging.
18 . The compound according to claim 17 wherein imaging is positron emission tomography (PET) imaging, single-photon emission computed tomography (SPECT) imaging, magnetic resonance imaging (MRI), or optical imaging.
19 . A method according to claim 15 , for assessing the status of a tumor, an injury, a stroke, a heart attack, in inflammation, an infection, or the response of a patient suffering from a tumor, from an infection, and/or from an inflammation, from injury, from stroke, from heart attack, to an anti-tumor therapy, to anti-infection therapy and/or to anti-inflammatory therapy, respectively.
20 . A method for detecting the progression of a tumor, of an injury, of a stroke, of a heart attack, of an infection, and/or of an inflammation in a tissue of a patient, comprising
a) administering a compound according to claim 1 to a patient, and
b) measuring the amount or the concentration of the compound in the tissue.
21 . A method for obtaining a compound according to claim 1 .
22 . A kit comprising a compound of claim 1 .